Hepatology Research最新文献

{"title":"Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational Study.","authors":"Takamichi Ishii, Junichi Shindoh, Ikuo Nakamura, Seiko Hirono, Masaki Wakasugi, Akihiko Ichida, Takashi Hamada, Hajime Matsushima, Takahiro Nishio, Yukio Tokumitsu, Hidenori Takahashi, Yuji Morine, Shinichiro Yamada, Akiyoshi Nakakura, Susumu Eguchi, Kiyoshi Hasegawa, Etsuro Hatano","doi":"10.1111/hepr.70027","DOIUrl":"https://doi.org/10.1111/hepr.70027","url":null,"abstract":"<p><strong>Aim: </strong>This study is aimed to evaluate the safety and outcomes of surgical resection in patients with hepatocellular carcinoma (HCC) treated with systemic therapy, address the therapeutic benefit, and identify candidates for surgery after systemic treatment.</p><p><strong>Methods: </strong>This retrospective cohort study was conducted at seven high-volume centers in Japan, enrolling patients who underwent surgical resection for HCC after systemic drug therapy. Pre- and post-treatment resectability criteria and oncological outcomes (progression-free survival [PFS], overall survival [OS], pathological complete response [pCR], and postoperative complications) were analyzed.</p><p><strong>Results: </strong>The cohort included 96 patients (mean age 68.3 years). The first-line systemic therapies were sorafenib, lenvatinib, atezolizumab plus bevacizumab, and durvalumab plus tremelimumab (n = 2/60/33/1, respectively). The pre-treatment oncological resectability criteria were R/BR1/BR2 (n = 8/42/46, respectively) and the pre-surgery criteria were R/BR1/BR2 (n = 13/41/42, respectively). Surgical procedures included 87 hepatectomies (42 major, 45 minor) and 9 non-hepatectomy procedures. The median PFS was 0.9 years with 1-, 2-, and 5-year PFS rates of 45.2%, 35.0%, and 25.6%, and the median OS was 4.0 years with 1-, 2-, and 5-year OS rates of 86.1%, 64.5%, and 39.9%, respectively. R0/1 resection rate was 83.3%, and pCR rate was 18.8%. Postoperative complications (Clavien-Dindo grade ≥ IIIa) occurred in 18.8%, with a 30-day mortality rate of 0% and a 90-day mortality rate of 4.2%. R0/1 resection was independently associated with better PFS and OS.</p><p><strong>Conclusions: </strong>Surgical resection following systemic therapy demonstrated favorable safety and long-term outcomes in advanced HCC. R0/1 resection is a key determinant of the prognosis.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity Decreases Liver-Related Death in Patients With Cirrhosis: A Retrospective Propensity Score-Matched Study.","authors":"Kei Endo, Keisuke Kakisaka, Tamami Abe, Hiroaki Abe, Ippeki Nakaya, Takuya Watanabe, Akiko Suzuki, Yuichi Yoshida, Takayoshi Oikawa, Akio Miyasaka, Hidekatsu Kuroda, Takayuki Matsumoto","doi":"10.1111/hepr.70022","DOIUrl":"https://doi.org/10.1111/hepr.70022","url":null,"abstract":"<p><strong>Aims: </strong>To determine the impact of obesity on the prognosis of patients with liver cirrhosis.</p><p><strong>Methods: </strong>This present retrospective observational study enrolled 482 patients without hepatocellular carcinoma (HCC). The patients were evaluated for obesity during the subsequent 8-year follow-up period. Obesity was defined as a body fat percentage of ≥ 25.8% for men and ≥ 36.5% for women as measured using a bioelectrical impedance analysis. After propensity score matching was adjusted for age, sex, etiology, and severity of liver disease, 185 patients were assigned to either the obese or nonobese group. The prognostic impact of obesity in patients with cirrhosis was evaluated by differentiating between liver-related and nonliver-related deaths.</p><p><strong>Results: </strong>The median observation period was 4.2 years. The cumulative incidence of liver-related deaths was significantly higher in the nonobese group than in the obese group (P = 0.02), whereas there was no significant difference in the cumulative incidence of nonliver-related deaths between the obese and nonobese groups (P = 0.70). Multivariate competing risk analyses revealed that a nonviral etiology (hazard ratio [HR], 5.43), decompensated cirrhosis (HR, 5.22), sarcopenia (HR, 2.28), and obesity (HR, 0.49) were independently associated with liver-related death. Among patients with a nonviral etiology, female patients sarcopenia, and patients with decompensated cirrhosis, the cumulative incidence of liver-related death was significantly higher in nonobese patients than in obese patients (P < 0.01, 0.04, 0.03, and 0.01, respectively).</p><p><strong>Conclusions: </strong>Obesity decreased liver-related death in patients with cirrhosis, particularly in female patients, patients with a nonviral etiology, and patients with sarcopenia.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.","authors":"Takeshi Hatanaka, Shigeo Shimose, Takanori Ito, Joji Tani, Tetsu Tomonari, Issei Saeki, Yasuto Takeuchi, Kyo Sasaki, Yuichi Honma, Ryu Sasaki, Naoki Yoshioka, Takehito Naito, Mamiko Takeuchi, Tetsuya Yasunaka, Masahiro Sakata, Hideki Iwamoto, Satoshi Itano, Yuki Kanayama, Tomotake Shirono, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Sohji Nishina, Motoyuki Otsuka, Hideki Kobara, Taro Takami, Tetsuji Takayama, Takumi Kawaguchi, Hiroki Kawashima, Masaru Harada, Hisamitsu Miyaaki, Satoru Kakizaki","doi":"10.1111/hepr.70023","DOIUrl":"https://doi.org/10.1111/hepr.70023","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to evaluate the association between the efficacy of durvalumab plus tremelimumab (Dur/Tre) and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>A total of 239 patients with HCC who received Dur/Tre between March 2023 and October 2024 at multiple institutions in Japan were retrospectively analyzed. Patients were categorized into three groups based on underlying liver disease: viral-related HCC (n = 126), MASLD-related HCC (n = 30), and nonviral, non-MASLD HCC (n = 83).</p><p><strong>Results: </strong>The overall response rates (ORR) were 17.5%, 16.7%, and 19.3% in viral-related HCC, MASLD-related HCC, and nonviral, non-MASLD HCC, respectively. The disease control rates (DCR) were 44.4%, 46.7%, and 51.8%, respectively. No significant differences in ORR (p = 0.6) or DCR (p = 0.9) were observed among the three groups. The median PFS was 3.7 months (95% CI, 2.8-4.9) in patients with viral-related HCC, 3.6 months (95% CI, 2.3-4.8) in patients with MASLD-related HCC, and 4.4 months (95% CI, 2.6-5.8) in patients with nonviral, non-MASLD HCC. The median OS was 14.4 months (95% CI, 9.8-NA) in patients with viral-related HCC and 11.0 months (95% CI, 6.4-NA) in patients with MASLD-related HCC, whereas it was not reached in patients with nonviral, non-MASLD HCC. No statistically significant differences in PFS (p = 1.0) and OS (p = 0.3) were found among the groups.</p><p><strong>Conclusions: </strong>Dur/Tre showed comparable efficacy in MASLD-related HCC and other etiologies, warranting confirmation in larger cohorts.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Bile Duct Loss in Early-Stage Primary Biliary Cholangitis: A Long-Term Observational Study.","authors":"Taiki Okumura, Takefumi Kimura, Takanobu Iwadare, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Satoru Joshita, Michiharu Komatsu, Naoki Tanaka, Akihiro Matsumoto, Tomoyuki Nakajima, Mai Iwaya, Masahiro Umemura, Kazuhito Kawata, Kenichi Harada, Takeji Umemura","doi":"10.1111/hepr.70018","DOIUrl":"10.1111/hepr.70018","url":null,"abstract":"<p><strong>Background & aims: </strong>Primary biliary cholangitis (PBC) is a chronic, slowly progressive, and autoimmune liver disease. This study aimed to establish the clinicopathological features that accurately predict long-term prognosis in patients with early-stage PBC.</p><p><strong>Methods: </strong>The present long-term (8.8 years), multicenter, and retrospective investigation enrolled 274 treatment-naïve PBC patients who had undergone liver biopsy. Among them, 207 patients with albumin-bilirubin (ALBI) grade 1 were categorized as clinical early-stage, and 230 patients with Nakanuma stage 1/2 were classified as pathological early-stage. The prognostic factors related to the time to liver-related events (LRE) were statistically evaluated.</p><p><strong>Results: </strong>Cox regression analysis identified Nakanuma bile duct loss score of ≥ 1 as a significant independent factor associated with LRE development in clinical early-stage PBC patients (hazard ratio [HR] 12.89, 95% confidence interval [95% CI] 1.60-103.96, P = 0.016). Kaplan-Meier testing revealed that the cumulative incidence of LRE was significantly higher in patients with bile duct loss score of ≥ 1 than in those with bile duct loss score 0 (log-rank test; P < 0.001). Similarly, bile duct loss score could predict LRE in pathological early-stage PBC patients, as confirmed by both multivariable Cox regression (HR 6.60, 95% CI 1.37-31.86, P = 0.019) and Kaplan-Meier (log-rank test; P < 0.001) analyses.</p><p><strong>Conclusions: </strong>Nakanuma bile duct loss score may be a valuable prognostic indicator in the early clinical and pathological stages of PBC.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Experience With Nalmefene in Alcohol-Related Liver Disease: A Real-World Retrospective Study.","authors":"Junichi Hanatani, Tadashi Namisaki, Hiroaki Takaya, Shinya Sato, Masayoshi Takami, Hiroyuki Masuda, Yuki Tsuji, Norihisa Nishimura, Takashi Inoue, Akihiko Shibamoto, Satoshi Iwai, Yukihisa Fujinaga, Koh Kitagawa, Kosuke Kaji, Akira Mitoro, Kiyoshi Asada, Hitoshi Yoshiji","doi":"10.1111/hepr.70019","DOIUrl":"https://doi.org/10.1111/hepr.70019","url":null,"abstract":"<p><strong>Background: </strong>Complete abstinence is the cornerstone of alcohol-related liver disease (ALD) management. However, many patients struggle to achieve or sustain abstinence, prompting growing interest in harm reduction strategies, particularly pharmacological interventions to reduce alcohol intake. Nalmefene, an opioid receptor modulator, has shown efficacy in reducing alcohol consumption among individuals with alcohol dependence. However, its effects on hepatic parameters in ALD have not been well studied in real-world settings.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of nalmefene in patients with ALD, focusing on changes in alcohol consumption, liver function, and hepatic reserve capacity.</p><p><strong>Methods: </strong>The present retrospective observational study included 21 patients with ALD who received nalmefene therapy at our institution between September 2019 and December 2023. Data on alcohol intake, liver function tests, hepatic reserve capacity, and alcohol use disorders identification test scores were collected at baseline and after 6 months of treatment. Adverse events were also recorded.</p><p><strong>Results: </strong>Within 1 month of initiating nalmefene, significant reductions in heavy drinking days and total alcohol consumption were observed. These reductions were accompanied by improvements in liver function parameters. However, no statistically significant changes in hepatic reserve capacity were noted. Most adverse events were mild to moderate (Grade 1 or 2), and no serious adverse events occurred.</p><p><strong>Conclusion: </strong>Nalmefene appears to be a safe and effective pharmacological option for reducing alcohol intake and improving liver function in patients with ALD. These findings support its use as part of a harm reduction approach for those unable to achieve complete abstinence.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Letter to Editor: \"Beyond Biochemical Response: Rethinking Risk Stratification and Endpoint Hierarchy in PBC\".","authors":"Yukihisa Fujinaga, Tadashi Namisaki, Kosuke Kaji, Hitoshi Yoshiji","doi":"10.1111/hepr.70017","DOIUrl":"https://doi.org/10.1111/hepr.70017","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOX9 Is a Key Factor for the Postnatal Maturation of the Intrahepatic Bile Duct Network.","authors":"Hiroki Hirao, Daiki Yoshii, Shigeyuki Esumi, Ahmad Adawy, Yukio Fujiwara, Masaki Honda, Yuji Yokouchi, Taizo Hibi, Yoshihiro Komohara","doi":"10.1111/hepr.70012","DOIUrl":"https://doi.org/10.1111/hepr.70012","url":null,"abstract":"<p><strong>Aim: </strong>The sex-determining region Y-box 9 (SOX9) plays a critical role in the development of intrahepatic bile ducts (IHBDs) during the embryonic stage. However, its role in postnatal IHBD maturation remains unclear. This study aimed to investigate the function of SOX9 in the postnatal development of the bile duct network, with particular emphasis on its role in structural organization.</p><p><strong>Methods: </strong>Three-dimensional imaging analysis was conducted using a mouse model in which SOX9 deficiency is predominant after birth to assess the structural organization of IHBDs. Additionally, transcriptional profiling was performed in Sox9 conditional knockout (cKO) mice to elucidate mechanisms underlying abnormal IHBD morphogenesis.</p><p><strong>Results: </strong>In Sox9 cKO mice, bile ductules were significantly reduced in the middle region at 1, 5, and 10 weeks, whereas a ductular reaction was observed in the peripheral region at 5 and 10 weeks, likely in response to cholestatic liver injury, compared to control mice. SOX9 was essential for IHBD maturation and structural organization, in particular, in establishing connections between bile ductules and also between bile ductules and bile canaliculi. Furthermore, transcriptome analysis of Sox9 cKO mice revealed activation of compensatory pathways involved in bile acid transport and metabolism, whereas intercellular adhesion pathways were downregulated.</p><p><strong>Conclusions: </strong>These findings underscore the pivotal role of SOX9 in postnatal bile duct network development, demonstrating its critical involvement in maintaining structural organization. The results suggest that SOX9 plays a more substantial role in bile duct maturation than previously recognized, providing new insights into its regulatory mechanisms in liver development.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep-Learning-Aided Quantification of Steatohepatitis-Associated Pathological Findings in Liver Specimens.","authors":"Shinji Mizuochi, Reiichiro Kondo, Shusuke Kawamura, Takashi Nishimura, Hiroko Iijima, Masayoshi Kage, Hironori Kusano, Yutaro Mihara, Yoshiki Naito, Masamichi Nakayama, Hirohisa Yano, Jun Akiba","doi":"10.1111/hepr.70015","DOIUrl":"https://doi.org/10.1111/hepr.70015","url":null,"abstract":"<p><strong>Background: </strong>Although semi-quantitative scoring is a common method for quantifying histopathological findings, semi-quantitative evaluation may lead to errors in objectivity and reproducibility depending on the histological findings. We developed a deep learning model to quantify steatohepatitis-associated pathological findings from liver specimens.</p><p><strong>Methods: </strong>Eighteen liver specimens of steatohepatitis, and eight liver specimens of chronic hepatitis were used to train AI (convolutional neural network), and construct an AI to quantify steatohepatitis-associated pathological findings. The AI model measured percentages of the steatosis area (%Steatosis), ballooning area (%Ballooning), and fibrosis area (%Fibrosis) in the liver biopsy specimens. Subsequently, 233 patients who underwent ultrasonography before liver biopsy were used for validation. Histological findings of these liver specimens were evaluated by three evaluators with expertise in liver pathology.</p><p><strong>Results: </strong>%Steatosis, %Ballooning, and %Fibrosis were measured for all liver specimens. In all patients, %Steatosis was strongly correlated with the histological steatosis grade (R = 0.78, p < 0.001) and ultrasound controlled attenuation parameter (R = 0.51, p < 0.001). In the liver tissues of 47 nonalcohol-related steatotic liver disease (NASLD) patients, %Ballooning was correlated with the histological ballooning grade (R = 0.4, p < 0.01). In the NASLD patients, %Fibrosis was strongly correlated with the histological fibrosis stage (R = 0.72, p < 0.001), and ultrasound shear wave elastography (R = 0.7, p < 0.001).</p><p><strong>Conclusion: </strong>Deep-learning-aided pathology can quantify steatohepatitis-associated pathological findings from liver tissue specimens. This AI model is a tool used to quantify the steatohepatitis-associated pathological findings and is not an algorithm to diagnose steatohepatitis.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144845812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Community-Based Micro-Elimination of Hepatitis C Virus in a Defined Rural Cohort: Outcomes From the Nagawa Project.","authors":"Hiroyuki Kobayashi, Masao Ota, Katsuhiko Matsuzaki, Hiromi Yamada, Daiki Aomura, Nao Joshita, Hajime Midorikawa, Takayuki Nimura, Kosuke Yamaka, Yukifumi Kurasawa, Kazuhiro Suyama, Hiromichi Misawa, Satoru Joshita","doi":"10.1111/hepr.70016","DOIUrl":"https://doi.org/10.1111/hepr.70016","url":null,"abstract":"<p><strong>Background and aims: </strong>Hepatitis C virus (HCV) infection remains a global public health concern, with many carriers remaining undiagnosed because of its asymptomatic nature. Although Japan was previously considered to be on track for national HCV elimination by 2030, recent global modeling studies and updated elimination dashboards indicate that Japan is currently not on track. This underscores the importance of locally coordinated efforts to detect residual cases. Micro-elimination has recently emerged as a pragmatic and scalable approach by targeting defined populations or geographic areas. The Nagawa Project sought to identify HCV positive individuals through community-wide screening and directing viremic cases to appropriate direct-acting antiviral (DAA) therapy. The present study describes the implementation and outcomes of this cohort-based HCV micro-elimination strategy.</p><p><strong>Methods: </strong>All 5027 adult residents of Nagawa town, Japan, aged ≥ 20 years were prospectively targeted for HCV antibody testing through routine health check-ups, outpatient visits, and mailed invitations between June 2021 and March 2024. HCV Antibody positive individuals underwent additional HCV core antigen testing to confirm viremia.</p><p><strong>Results: </strong>A total of 3121 residents (62.1%) underwent HCV antibody testing. Testing rates were significantly higher in early-stage elderly (65-74 years; 73.7%) residents than in both adult (20-64 years; 54.5%) (p < 0.001) and late-stage elderly (≥ 75 years; 66.7%) (p < 0.001) residents. Twenty-eight individuals (0.897%) were HCV antibody positive, with three cases (0.096%) confirmed as viremic. Antibody positivity was significantly higher in late-stage elderly residents (1.91%; p < 0.001 vs. adult and p = 0.031 vs. early-stage elderly residents). Two viremic individuals received DAA therapy and achieved a sustained virological response. After adjusting for age and sex by propensity score matching, no significant difference in overall survival was observed between HCV antibody positive and negative individuals.</p><p><strong>Conclusion: </strong>The Nagawa Project illustrates the success of a locally coordinated HCV micro-elimination approach. It offers a practical framework for identifying and managing residual HCV infections, contributing to progress toward Japan's alignment with the World Health Organization's 2030 HCV elimination goals.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.","authors":"Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Kosuke Matsui, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo","doi":"10.1111/hepr.70011","DOIUrl":"https://doi.org/10.1111/hepr.70011","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the safety and efficacy of durvalumab plus tremelimumab (Dur/Tre) in older adults with unresectable hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>A total of 345 patients with HCC who received Dur/Tre were included in this study. Using propensity score matching, we compared outcomes between older (aged ≥ 75 years; n = 120) and younger individuals (n = 120).</p><p><strong>Results: </strong>The median progression-free survival (PFS) was 3.3 months in the older group and 4.5 months in the younger group (p = 0.271). The median overall survival (OS) was 17.0 months in older individuals and 19.2 months in younger individuals (p = 0.598). No statistically significant differences were observed in the therapeutic response between the two groups (p = 0.264). Additionally, the incidence of immune-mediated adverse events (AEs) did not differ significantly between older and younger individuals. Multivariate analyses revealed that age group (older vs. younger) was not an independent prognostic factor for PFS (p = 0.250) or OS (p = 0.489). In a subgroup analysis stratifying older individuals into three age categories (75-79, 80-84, and ≥ 85 years), no significant differences were observed in the cumulative OS or PFS across the subgroups (p = 0.308 and 0.783). Similarly, the incidence of immune-mediated AEs did not differ significantly among the age categories.</p><p><strong>Conclusions: </strong>Dur/Tre appears to be a safe and effective treatment option for patients with HCC, regardless of age. Dur/Tre appears to be a safe and effective treatment option for patients with unresectable HCC, regardless of age.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}